Coherus Biosciences | CHRS - Le Coût Des Ventes





Le Coût Des Ventes Changement Date
AbbVie USD 4.29B 73M 2026-06
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.87B 271M 2026-06
Baxter International USD 1.93B 118M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.27B 309M 2026-06
Fujifilm JPY 550.58B 40.74B 2026-03
Gilead Sciences USD 1000M 445M 2026-06
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Merck USD 3.14B 200M 2026-06
Myriad Genetics USD 63M 1.1M 2025-12
Pacira USD 58.49M 7.75M 2026-06
Perrigo USD 708.9M 65.2M 2026-06
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06
Xencor USD 61.66M 50.95M 2025-06
Zoetis USD 704M 32M 2026-06